VDAC1, mitochondrial dysfunction, and Alzheimer's disease

被引:173
|
作者
Shoshan-Barmatz, Varda [1 ]
Nahon-Crystal, Edna
Shteinfer-Kuzmine, Anna
Gupta, Rajeev
机构
[1] Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel
基金
以色列科学基金会;
关键词
Alzheimer's disease; Apoptosis; Metabolism; Mitochondria; Voltage-dependent anion channel 1; DEPENDENT ANION CHANNEL; PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; OXIDATIVE-PHOSPHORYLATION GENES; ADENINE-NUCLEOTIDE TRANSLOCASE; AMYLOID-BETA-PROTEIN; LIPID RAFTS; PLASMA-MEMBRANE; CELL LIFE; PRECURSOR PROTEIN;
D O I
10.1016/j.phrs.2018.03.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Alzheimer's disease (AD) is an age-related neurodegenerative disorder. Although an accumulation of brain amyloid-beta (A beta) peptide and hyperphosphorylated tau protein have been implicated in the pathogenesis of AD, the etiology of the disease remains unclear. Mitochondrial dysfunction has been identified as an early event in AD pathogenesis and is reflected by reduced metabolism, disruption of Ca2+ homeostasis, and increased levels of reactive oxygen species, lipid peroxidation, and apoptosis. The focus of this review is the involvement of mitochondrial dysfunction in AD, and specifically, the role of the voltage-dependent anion channel 1 (VDAC1), which has been linked to AD pathogenesis. VDAC1 is a multi-functional protein, expressed in the mitochondria and other cell compartments, including the plasma membrane. The protein regulates the main metabolic and energetic functions of the cell, including Ca2+ homeostasis, oxidative stress, and mitochondria-mediated apoptosis. VDAC1 represents a hub protein that interacts with over 150 other proteins including phosphorylated tau, A beta, and gamma-secretase, and participates in their toxicity. The high levels of VDAC1 demonstrated post-mortem in the brains of AD patients and in amyloid precursor protein (APP) transgenic mice prompted the hypothesis that the protein may be associated with neuronal cell destruction since over-expression of VDAC1 triggers cell death. Thus, targeting mitochondrial dysfunction via VDAC1, to prevent this pro-apoptotic activity, could represent a novel strategy for inhibiting cell death. In addition, the review also discusses possible VDAC1 involvement in the link between AD and diabetes and the inverse association between cancer and AD.
引用
收藏
页码:87 / 101
页数:15
相关论文
共 50 条
  • [1] Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease?
    Reddy, P. Hemachandra
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2013, 1832 (01): : 67 - 75
  • [2] Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology
    Ankit Verma
    Anna Shteinfer-Kuzmine
    Nikita Kamenetsky
    Srinivas Pittala
    Avijit Paul
    Edna Nahon Crystal
    Alberto Ouro
    Vered Chalifa-Caspi
    Swaroop Kumar Pandey
    Alon Monsonego
    Noga Vardi
    Shira Knafo
    Varda Shoshan-Barmatz
    Translational Neurodegeneration, 11
  • [3] Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer's disease protects against mitochondrial dysfunction and mitigates brain pathology
    Verma, Ankit
    Shteinfer-Kuzmine, Anna
    Kamenetsky, Nikita
    Pittala, Srinivas
    Paul, Avijit
    Nahon Crystal, Edna
    Ouro, Alberto
    Chalifa-Caspi, Vered
    Pandey, Swaroop Kumar
    Monsengo, Alon
    Vardi, Noga
    Knafo, Shira
    Shoshan-Barmatz, Varda
    TRANSLATIONAL NEURODEGENERATION, 2022, 11 (01)
  • [4] Correction: Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology
    Ankit Verma
    Anna Shteinfer-Kuzmine
    Nikita Kamenetsky
    Srinivas Pittala
    Avijit Paul
    Edna Nahon Crystal
    Alberto Ouro
    Vered Chalifa-Caspi
    Swaroop Kumar Pandey
    Alon Monsonego
    Noga Vardi
    Shira Knafo
    Varda Shoshan-Barmatz
    Translational Neurodegeneration, 12
  • [5] Reduced VDAC1, Maintained Mitochondrial Dynamics and Enhanced Mitochondrial Biogenesis in a Transgenic Tau Mouse Model of Alzheimer's Disease
    Vijayan, Murali
    Reddy, P. Hemachandra
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
  • [6] Targeting VDAC: A potential therapeutic approach for mitochondrial dysfunction in Alzheimer's disease
    Yang, Yaqian
    Jia, Xiaotao
    Yang, Xinmao
    Wang, Jie
    Fang, Yan
    Ying, Xiaoping
    Zhang, Meiqian
    Wei, Jing
    Pan, Yanfang
    BRAIN RESEARCH, 2024, 1835
  • [7] VDAC1 and the mitochondrial permeability transition
    Krauskopf, A
    Nicolosi, L
    Soriano, ME
    Petronilli, V
    Craigen, WB
    Bernardi, P
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 2004, 1658 : 258 - 258
  • [8] Amyloid-β peptide alters VDAC1 electrophysiology and reduces mitochondrial respiration in an in vitro model of Alzheimer's disease
    Cavallaro, F.
    Cubisino, S. A. M.
    Caruso, P.
    Reina, S.
    Messina, A.
    Magri, A.
    FEBS OPEN BIO, 2024, 14 : 402 - 402
  • [9] Reduced VDAC1 Protects Against Alzheimer's Disease, Mitochondria, and Synaptic Deficiencies
    Manczak, Maria
    Sheiko, Tatiana
    Craigen, William J.
    Reddy, P. Hemachandra
    JOURNAL OF ALZHEIMERS DISEASE, 2013, 37 (04) : 679 - 690
  • [10] Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer's disease protects against mitochondrial dysfunction and mitigates brain pathology (vol 11, 58, 2022)
    Verma, Ankit
    Shteinfer-Kuzmine, Anna
    Kamenetsky, Nikita
    Pittala, Srinivas
    Paul, Avijit
    Crystal, Edna Nahon
    Ouro, Alberto
    Chalifa-Caspi, Vered
    Pandey, Swaroop Kumar
    Monsonego, Alon
    Vardi, Noga
    Knafo, Shira
    Shoshan-Barmatz, Varda
    TRANSLATIONAL NEURODEGENERATION, 2023, 12 (01)